You face a complex gatekeeper when bringing food, drugs, devices, or other regulated goods into the U.S., and understanding FDA imports lets you move shipments faster and avoid costly holds. Mastering FDA import rules, electronic entry requirements, and documentation can cut clearance delays and protect your supply chain.
This article FDA Imports breaks down the regulatory process you must navigate, the common compliance pitfalls that trigger detentions, and practical steps you can take to streamline entries through ACE and other systems. Expect clear guidance on registration, prior notices, filing entries, and remedies designed to keep your products moving and compliant.
Regulatory Process Overview
You will need to provide specific entry data, support documents, and a clear point of contact. The agency performs electronic screening, may detain or refuse shipments that appear violative, and expects timely responses to requests for evidence.
Submission Requirements
You must file an entry with U.S. Customs and Border Protection (CBP) and submit required FDA data electronically through the Automated Commercial Environment (ACE). Required fields typically include product description, country of origin, manufacturer, consignee, and FDA Product Code or Harmonized Tariff Schedule (HTS) number.
Prior Notice is required for certain food shipments; missing Prior Notice can delay release or lead to refusal. For human drugs, devices, and biologics, you must provide registration and listing numbers when applicable.
Provide accurate importer of record and consignee information, and ensure your customs broker transmits data before arrival. Keep copies of commercial invoices, bills of lading, and certificates (e.g., Free Sale, GMP) ready to upload if requested.
Screening and Review Procedures
After ACE submission, CBP forwards data to FDA for automated risk screening through systems such as PREDICT. The screening compares your entry data against intelligence, import alerts, and past refusals to generate a risk classification. High-risk hits can trigger electronic stops, detention, or sampling at the point of entry.
If FDA suspects a violation based on appearance, you may present evidence to rebut that appearance or bring goods into compliance. FDA has statutory authorities (e.g., detention and refusal) and works with CBP to coordinate physical examinations, laboratory analysis, and administrative hearings when necessary.
Common Documentation Errors
Incorrect or missing product codes and HTS numbers cause many hold-ups; ensure the FDA Product Code matches the actual product and labeling. Incomplete manufacturer or lot information, vague product descriptions, and mismatched weight or quantity figures also prompt manual reviews or detentions.
Failure to provide required certificates (e.g., Prior Notice for foods, Free Sale for certain cosmetics) or to list registration numbers for regulated facilities frequently leads to refusal. Maintain consistent documentation across invoice, entry paperwork, and electronic filings to minimize discrepancies that trigger additional inspection.
Compliance Challenges and Solutions
You need clear processes for accurate product classification, compliant labeling and packaging, and rapid response when imports are held. Each area demands specific documentation, testing, and assigned responsibilities to prevent delays and fines.
Product Classification Issues
You must determine whether an item is a drug, device, biologic, food, or cosmetic; misclassification can trigger refusals and import alerts. Start by comparing product intended use and claims to FDA definitions, and retain written rationale for the classification.
Use these steps:
- Review product labeling and instructions for intended use statements.
- Consult FDA product codes and CFR definitions (21 CFR) to match categories.
- Perform bench testing or obtain certificates when composition is ambiguous.
Assign responsibility to a regulatory or compliance lead who documents decisions, maintains samples, and updates classification when formulations change. If uncertain, submit a premarket submission or request FDA guidance to reduce risk. Keep trade documentation (commercial invoice, bill of lading, packing list) aligned with the classification to avoid customs mismatches.
Labeling and Packaging Guidelines
You must comply with FDA labeling rules for content, claims, language, and country of origin marking to avoid detention or misbranding enforcement. Ensure all required elements appear: product identity, net quantity, manufacturer name and address, ingredient declarations, and any special statements (e.g., Rx-only).
Follow these actions:
- Create a labeling checklist tied to the product category and 21 CFR requirements.
- Verify claim language—avoid implied therapeutic claims on foods or cosmetics that would reclassify them as drugs.
- Translate mandatory information where required and ensure placement meets readability standards.
Maintain master label files and change-control procedures so packaging revisions trigger regulatory review. Conduct label reviews before production runs and keep photographic evidence of final packaging for customs and FDA inspections.
Managing Import Holds
When CBP or FDA places a hold or issues a Notice of Action (NOA), you must act quickly to prevent prolonged detention and financial loss. Identify whether the issue is paperwork, suspected contamination, misbranding, or entry in an import alert.
Take these steps immediately:
- Assemble documentation: entry paperwork, COA, lab test results, and distribution records.
- Request testing or reconditioning if contamination or quality is suspected.
- Engage counsel or a customs broker experienced with 801(b) and NOA responses when legal or technical disputes arise.
Track timelines strictly—FDA holds have deadlines for submission and response. If product meets criteria for release after corrective action, document remediation and update procedures to prevent recurrence. Maintain an escalation plan so procurement, quality, and legal teams respond within hours, not days.
